Asian Med News_October 2002

8/10/2019 Asian Med News_October 2002

1/12

Asian Medical Industry NewsMedical business opportunities in Asia

Editor:Paul Gordon

Asian Medical Industry News

is published by Proof 100 Ltd.

Proof 100 Limited

2nd Floor, Building 4H,

Tseng Lan Shue

Sai Kung, KowloonHong Kong

Tel: +852 2547 4548

Fax: +852 2335 9138

Email: [email protected]

Stock prices are quoted as at

October 25th unless otherwisestated. Exchange rates are

listed on page 12.

No material in this document

may be reprinted or distributed

without the express permission

of Proof 100 Limited.

Proof 100 Limited

REGULARFEATURES

Japanese share prices ................. 3

Patent decisions and approvals ... 6

Korean share prices.................... 7

Indian share prices ...................... 9

Conference calendar ............ 10-11

Companies listed ....................... 12

Issue No. 25 October 28th 2002

PROOF

100PUBLISHING

JAPANIressa to blame for 13 deaths ....................................................... 2

Chugai widens forecast loss ......................................................... 2

Banyu slashes profit forecast ....................................................... 2

Tanabe ties up with Novartis on antagonists................................. 2

Kawasumi approved for needle device ........................................ 2

Hepatitis victims sue pharma firms ............................................... 2

Glaxo to work with Kissei ............................................................. 2

US prods Japan on pharma reform ............................................... 2

Japanese share price movements ................................................. 3

CHINA/TAIWANChina, US and Glaxo work together on HIV/AIDS ..................... 4

Shenzhen buys into LaserSight ..................................................... 4

China gives birth to digitized man ................................................. 4

Cardiovascular epidemic on the way ............................................ 4

Taiwan legislators reject biotech park........................................... 4

SOUTHEASTASIA

Thai government ready to make HIV pills .................................... 5

MerLion the exception for venture funds ..................................... 5

Judge dismisses counterfeit drug claims ....................................... 5

US firms heads for Malaysia and Singapore ................................ 5

Pharmaniaga ready for next step .................................................. 5

Pfizer Malaysia ready with three new drugs ................................ 5

Bongso faces FEER factor ........................................................... 5

KOREA

LG Life in US$40 million Genesoft deal ....................................... 6

Novartis sees Korea as biotech partner ....................................... 6

HIV costing economy billions ....................................................... 6

Why side-effects occur ................................................................ 6

Korean doctors to study longer ..................................................... 6

Korean share price movements .................................................... 7

INDIA

Dr Reddys to appeal one decision, applauds two others ............. 8

Ranbaxy enters South African HIV market ................................. 8

Shatha looking for US$25 million .................................................. 8

Lilly shines on Sun ........................................................................ 8

Corporate results ...........................................................................8

Indian share price movements ...................................................... 9

ASIAN MEDICAL INDUSTRY NEWS

HEAVY DISCOUNTS ON MEDICAL INDUSTRY REPORTS.FOR FREE SUBSCRIBERS ONLY. WWW.PROOF100.COM


2/12

Published by Proof 100 Ltd. For a free subscription,email [email protected] or visit www.proof100.com

Asian Medical Industry NewsI ssue No. 25, October 28th, 20022

JapanIressa to blame for 13 deaths

The Japanese health ministry has attributed 13 deaths

to the anticancer drug Iressa (gefitinib). The ministry

says 26 terminally ill cancer patients developed

interstitial pneumonia and other side effects afterbeing administered the drug, with half of them dying.

Shoji Kudo, a professor at Nippon Medical School,

noted that the mortality rate is higher than other

anticancer drugs although the incidence of non-fatal

side-effects was lower. Iressa, manufactured by

AstraZeneca, received expedited approval in just five

months in Japan because of its reported benefits for

people with progressive cancer. The firm has been

ordered to issue an emergency advisory to alert

medical institutions. The drug is still awaiting approval

in the US.

Chugai widens forecast loss

Drugmaker Chugai Pharmaceutical has increased

its forecast group net loss for the six months to

September. The firm says losses will now total around

26.4 billion (US$212 million), up from a previous

estimate of 18 billion (US$145 million). Chugai this

month became a subsidiary of Swiss pharmaceutical

multinational Roche Holdings (see Issue 24, p 2).

Banyu slashes profit forecast

Banyu Pharmaceutical, one of Japans larger

drugmakers, has warned that profits in the six months

to September 30th will be 31% lower than originally

expected. The company now says parent-only net

income will be 6.2 billion (US$49.8 million), down

from an originally forecast 9 billion

(US$72.4 million).

Tanabe ties up with Novartis on antagonists

Tanabe Seiyaku has reached an agreement with

Novartis Pharma to collaborate on the worldwide

research, development and commercialization of its

LFA-1 antagonists. Leukocyte function-associated

antigen-1 (LFA-1) is a cell adhesion molecule

(integrin) expressed on the surface of leukocytes

responsible for leukocyte trafficking and T cell co-

activation. The antagonists identified by Tanabe inhibit

leukocyte trafficking and T cell co-activation, so

could be useful for autoimmune disorders such as

rheumatoid arthritis and psoriasis, and for the

prevention of the rejection of organ transplantations.

Kawasumi approved for needle device

Kawasumi Laboratories America, a Florida-based

unit of Japans Kawasumi Laboratories, has received

US FDA clearance to market a needle safety device.

The device, K-Shield, protects oncology cliniciansfrom Huber needle stick injuries incurred while

removing needles from subcutaneous ports.

Hepatitis victims sue pharma firms

Three pharmaceutical companies and the Japanese

government are being sued by 16 hepatitis C patients

seeking 900 million (US$7.2 million) in damages

for negligence. Thirteen men and women have

brought a class action suit in Tokyo, while three

women have filed in Osaka. Twelve of the plaintiffs

say they contracted hepatitis C after being given

transfusions of tainted fibrinogen between 1984 and

1988. An estimated two million Japanese contracted

hepatitis C, mostly from blood transfusions and blood

products. More lawsuits are expected. The fibinogen

was produced by Green Cross, now part of

Mitsubishi Pharma. Both are being sued along with

another drugmaker, Nihon Seiyaku.

Glaxo to work with Kissei

GlaxoSmithKline has entered into a license

agreement with Kissei Pharmaceutical for the

Japanese companys selective inhibitors of renal

glucose transport for diabetes. Under the agreement,

Kissei has granted GlaxoSmithKline the exclusive

rights to develop and market the compounds

worldwide, excluding Japan, Korea, China and

Taiwan. Kissei will receive upfront fees, royalties,

and milestone payments from GlaxoSmithKline

related to development and commercialisation. Kissei

has almost completed preclinical studies with the most

advanced agent in the series, which is scheduled for

Phase I in the first quarter of 2003.

US prods Japan on pharma reform

The United States Trade Representative has included

pharmaceuticals and medical devices in a list of ten

sectors in Japan which it would like to see reformed.

The list was presented during the Asia Pacific

Economic Cooperation meeting in Los Cabos,

Mexico. The US says Japans healthcare system is

marked by systemic inefficiencies while the

medical market is hindered by regulatory barriers.


3/12

Asian Medical I ndustry NewsI ssue No. 25, October 28th, 20023


Japan

Stock Core Price () Price change since Mkt Cap

Company Code Exchange business Oct 25th Issue 24 1/1/02 1/1/01 (US$m)

Share price movements ranked by performance since Jan 1st

ASIAN MEDICAL INDUSTRY NEWS

KEEP UP TO DATE WITH THE PHARMACEUTICAL AND

MEDICAL DEVICE INDUSTRY IN ASIA

WWW.PROOF100.COM FOR A FREE SUBSCRIPTION

Tsumura 4540 Tokyo Herbal medicine 1,090 3.8% 139.6% 246.0% 616Nippon ChemiPhar 4539 Tokyo Pharmaceuticals 453 3.0% 90.3% 97.8% 134

Suzuken 9987 Tokyo Wholesale 3,300 0.3% 59.4% 10.0% 2,069

Kuraya Sanseido 7459 Tokyo Wholesale 867 3.5% 55.7% -5.1% 956

Nihon Kohden 6849 Tokyo Medical devices 427 3.6% 29.8% 44.7% 158

Hitachi Medical 6910 Tokyo Medical devices 1,530 7.0% 28.0% 30.8% 488

Shimadzu 7701 Tokyo Medical devices 372 26.1% 22.4% -2.9% 801

Sawai Pharmaceutical 4555 Tokyo Generics 1,620 -0.7% 16.5% 60.4% 138

Fuji Pharmaceutical 4554 Jasdaq Generics 440 2.3% 7.3% 41.0% 46

Toyama Chemical 4518 Tokyo Pharmaceuticals 406 -0.7% -1.0% -1.7% 491

Ono Pharma 4528 Tokyo Pharmaceuticals 3,980 0.8% -1.7% -9.5% 3,943

Olympus Optical 7733 Tokyo Medical devices 1,841 7.0% -2.3% -6.8% 3,929

Terumo Corp 4543 Tokyo Pharmaceuticals 1,619 3.8% -4.7% -35.2% 2,755

Vital-Net (Sun-S) 9916 Tokyo Wholesale 710 1.4% -5.3% -16.5% 239

Taisho Pharma 4535 Tokyo Pharmaceuticals 1,927 3.6% -6.5% -37.6% 5,298

Zeria Pharmaceutical 4559 Tokyo Pharmaceuticals 999 -0.1% -7.5% -10.4% 388

Azwell 9825 Osaka Wholesale 407 1.8% -7.5% -21.7% 296

Tanabe Seiyaku 4508 Tokyo Pharmaceuticals 1,080 5.1% -7.5% 12.5% 2,309

Yamanouchi Pharma 4503 Tokyo Pharmaceuticals 3,110 8.9% -10.1% -37.0% 9,063

Hisamitsu Pharma 4530 Tokyo Pharmaceuticals 1,593 11.9% -11.5% -19.7% 1,306

Takeda Chemical 4502 Tokyo Pharmaceuticals 5,180 4.9% -12.6% -23.4% 36,885

SSP 4537 Tokyo Pharmaceuticals 779 7.4% -17.6% -14.5% 763

Eisai 4523 Tokyo Pharmaceuticals 2,680 3.1% -17.8% -33.0% 6,409

Dainippon Pharma 4506 Tokyo Pharmaceuticals 1,038 1.4% -22.0% -45.1% 1,409Fujisawa Pharma 4511 Tokyo Pharmaceuticals 2,345 -0.6% -22.4% -38.0% 6,213

Mochida Pharma 4534 Tokyo Pharmaceuticals 571 -2.6% -25.4% -18.8% 666

Kaken Pharma 4521 Tokyo Pharmaceuticals 522 1.2% -26.9% -17.5% 398

Daiichi Pharma 4505 Tokyo Pharmaceuticals 1,853 -0.4% -27.3% -45.5% 4,283

Santen Pharma 4536 Tokyo Pharmaceuticals 1,050 4.0% -29.5% -53.3% 785

Chugai Pharma 4519 Tokyo Pharmaceuticals 1,006 8.3% -33.8% -47.1% 2,045

Sankyo 4501 Tokyo Pharmaceuticals 1,475 -1.5% -34.3% -46.2% 5,349

Shionogi 4507 Tokyo Pharmaceuticals 1,368 2.6% -38.9% -41.3% 3,844

Kyorin Pharma 4560 Tokyo Pharmaceuticals 1,989 19.8% -41.5% -26.3% 924

Banyu Pharma 4515 Tokyo Pharmaceuticals 1,096 -6.1% -43.8% -57.6% 2,333

Mitsubishi Pharma 4509 Tokyo Pharmaceuticals 816 1.4% -44.8% -9.3% 1,809


4/12



surgery. So far, only the United States and South

Korea have made their own digitized human. The

image is made from a human body specimen by taking

photos of cross sections of a 35-year-old Chinese

man with a digital camera and putting the data intothe computer. The computer then analyzed the data

and produced a three-dimensional image. Team

leader Professor Zhang Shiaoxiang said that their

creation of the man involved 2,518 cross sections,

with the thinnest slice at 0.1 mm. The digitised man

represents the result of a three-year effort by more

than 20 researchers from the Third Military Medical

University in Chongqing.

Cardiovascular epidemic on the way

Cardiovascular illness is due to reach epidemic

proportions in China and the country needs to make

preparations to deal with it, according to a senior

public health official. Kong Lingzhi of the Department

of Disease Control said cancer, cerebral vascular

disease and heart disease have become the top three

killers among Chinas 450 million urban residents.

She blamed lifestyle changes, with a lack of physical

exercise, unbalanced diets and smoking as major

factors. She advocates healthier lifestyles to fight

the epidemic but warns the country to prepare for

far higher medical bills.

Taiwan legislators reject biotech parkA proposal by Taiwans National Science Council

(NSC) to purchase land for a biomedical technology

park has been turned down by opposition legislators.The planned biomedical technology park covers 38.3

hectares of land in Chupei , Hsinchu County, close

to the Hsinchu Science-based Industrial Park. The

NSC proposed a purchase price of NT$4.45 billion

(US$128 million) for the land to build the park. That

was rejected by legislators as being too expensive.

Some legislators also said that the NSC lacks the

capability to integrate resources pertaining to bio-

tech R&D and related industries.

China/Taiwan

ATAGLANCEChina and high blood pressure

Around 100 million people in China suffer from

high blood pressure.Source: Chinese Ministry of Health

China, US and Glaxo work together

on HIV/AIDS in Yunnan

A team of Chinese and American researchers has

launched a clinical study of HIV/AIDS treatment inChinas AIDS-stricken Yunnan Province with the

objective of developing a strategy for nationwide

treatment. Through the pilot project, in which 300

patients are being treated with the triple combination

antiretroviral therapy the cocktail therapy the

researchers hope to develop affordable and effective

treatment methods for the some one million HIV

positive people in China.

The three-year study consists of a collaborative effort

between researchers from the Chinese Academy ofMedical Sciences (CAMS), the New York-based

Aaron Diamond AIDS Research Center, and the

Yunnan Provincial Center for Disease Prevention

and Control. The study is using Trizivir, a fixed-dose

antiretroviral combination tablet developed by

GlaxoSmithKline.

Shenzhen buys into LaserSight

US-based laser eye surgery equipment maker

LaserSight says it has received a previously

announced and delayed equity investment fromChina. The cash infusion strengthens the partnership

between LaserSight and Shenzhen New Industries

Medical Development, which operates in mainland

China and Hong Kong. The firm had pledged to

deliver the US$2 million investment by September

30th. However, the day after that deadline passed,

LaserSight agreed to give Shenzhen until October

20th to make the investment, which gives the Chinese

firm a 40% stake in LaserSight. Shenzhen aims to

distribute LaserSight equipment in mainland China,

Hong Kong, Macao and Taiwan. The company has

agreed to purchase US$10 million in LaserSight

products in a 12-month period. Thus far, LaserSight

has shipped US$1.1 million in products to Shenzhen.

China gives birth to digitized man

China has become only the third country in the world

to produce a three-dimensional digitized human. The

image will provide scientists and medical practitioners

with basic data to help with medical diagnosis and


5/12



Southeast AsiaThai government ready to make HIV pills

Thailands state drug-making agency says it will begin

immediate production of the AIDS drug didanosine

(ddI) following a court decision against the patent

holder, Bristol-Myers Squibb (see Issue 24, p 5).The GPO already produces didanosine in a powder

form, but AIDS activists say the tablets will be easier

for patients to take and will have fewer side-effects.

The agency will initially produce about 5,000 tablets

a day and will then scale up to produce greater

quantities, all for domestic consumption.The pills will

be sold at around Baht 20 (US$0.46) for a 125mg

tablet, less than half the BMS price.

MerLion the exception for venture funds

Singapores MerLion Pharmaceuticals says it has

almost completed a round of financing which will

give it at least S$18 million (US$10.2 million) in

funding from private investors. The announcement

comes as a survey released by law firm Rajah &

Tann shows that many firms are having great

difficulty finding cash. In a poll of 60 of Singapores

200 firms involved in the biomedical industry, over

60% said they were struggling to raise funds. Many

more said they were also having problems recruiting

top talent. MerLion was founded in July through the

privatization of Singapores Centre for Natural

Product Research (CNPR), a unit of the state-runInstitute of Molecular and Cell Biology. Under the

deal, it acquired all of CNPRs collection of plant

samples from Southeast Asia and the natural product

libraries of GlaxoSmithKline (see Issue 19, p4).

Judge dismisses counterfeit drug claims

A Singapore High Court judge has dismissed claims

by a Chinese pharmaceutical company that two

Singapore outfits have misled consumers into thinking

that they are selling its products. The judge ruled

that the herbal medicine, which is supposed to stopbleeding and heal wounds, had been sold in Singapore

for more than 20 years before the Chinese company

got its licence to manufacture its medicine. The

Yunnan Baiyao Group sued local firms Tong Jum

Chew and Tong Jum Chew Medical Store for passing

off the Camellia brand of Yunnan Paiyao as the

Chinese companys product. Judicial Commissioner

Choo Han Teck said that the local firms had not

attempted to mislead the public.

US firm heads for Malaysia and Singapore

Nabi, a drugmaker based in Florida, US, has signed

two international distribution agreements for its

hepatitis B drug. Under the agreements, Biotech

Medical of Malaysia and Innovative Biotech ofSingapore will become distributors in their home

markets for Nabi-HB. The value of the deal and the

potential market size for the drug were not given.

Nabi-HB is approved in the US for prevention of

hepatitis B virus infection upon acute exposure. The

drug is a sterile solution of human antibodies.

Pharmaniaga ready for next step

Malaysian integrated healthcare company

Pharmaniaga says it will maintain the growth rates

of the last five years as it embarks on an expansion

strategy in Asia. Managing director Tan See Yin says

the company, which registered sales of RM 543

million (US$143 million) last year, has had a

compound annual growth rate in turnover of 25%

for the last five years. Tan says he is seeking to

position Pharmaniaga as a significant player in the

regional and global healthcare industry. As part of

that move, the firm has launched a new corporate

identity and logo.

Pfizer Malaysia ready with three new drugsThe Malaysian subsidiary of Pfizer plans to market

new drugs for arthritis, migraine and mental disorder

in 2003, according to chief executive officer and

managing director Radzmi Rahmat. The company

head also said Viagra (sildenafil citrate) had

surpassed earlier forecasts in the three years since

it was introduced in the local market and the

company looked forward to continued strong

demand. He dismissed the threat of traditional herbal

medicine alternatives, saying they work in a different

manner.

Bongso faces FEER factor

Ariff Bongso, a professor at the National University

of Singapore, has won Gold in the Far Eastern

Economic Reviews Asian Innovation Awards. Prof

Bongso and his team this year successfully grew a

human embryonic stem cell line without the use of

mouse cells. The work could eliminate one of the

risks of using stem cells in therapies the chance

that mouse pathogens will leap to humans.


6/12



Korea

PATENTDECISIONSANDPRODUCTAPPROVALS

Company Product Result and Asian impact

Kawasumi Laboratories K-Shield needle safety US FDA approval. See page 2.

device

Dr Reddys Laboratories Amlodipine maleate US FDA issues approvable letter. Amlodipine maleate

the generic version of Pfizers Norvasc. See page8.

LG Life in US$40 million GeneSoft

deal

LG Life Sciences has signed a US$40.5 million deal

to transfer antibiotic-related technology to GeneSoft,a California-based biopharmaceutical company. LG

Life, a pharmaceutical unit of the LG Group, also

agreed to receive 4.59 million shares of GeneSoft

a 14% stake in the US firm in return for the

technology transfer. The technology is related to the

production ofFactive,a quinoline antibiotic. LG says

it will receive royalties once the product hits the

market. GeneSoft, in return, will have the right to

produce the drugs and sell them in the US and

European markets.

In a separate move, LG Life has appointed

Malaysias DuoPharma Biotech to promote LGs

Hyal and Hyruan products in Malaysia. Hyal is a

visco-elastic solution used for intra-ocular surgery

while Hyruan is used as a lubricant for painful joints

and knees. DuoPharma aims to take a 20% share

of what it estimates to be a RM 8-10 million

(US$2.1-2.6 million) market.

Novartis sees Korea as biotech partner

Swiss multinational Novartis says it hopes to workwith South Korea in its mission to discover new cures

for diseases. Alexandre Jetzer, a member of the board

of directors at Novartis, in an interview with the

Korea Times, said he visited Korea last week to take

part in the 2002 Osong International Bio Exposition

and meet with scientists and government officials

regarding future investment projects in Korea. He

said he feels South Korea has many strong points in

the biotech industry which makes it attractive for

future investment, such as its high-quality human

resources.

HIV costing economy billions

HIV/AIDS is costing Korea around Won 240 billion

(US$195 million) a year in loss of labor, according to

a study by the Korea Institute for Health and Social

Affairs. The estimate, for 2001, includes bothabsolute and potential loss of productivity. The figure

is well above the Won 193 billion (US$157 million)

estimate for 2000 and five times as high as in 1994.

In the first six months of 2002 the estimated loss

was Won 128 billion (US$104 million). The figures

are based on a calculation of the amount of workers

who would have contributed to gross domestic

product during their lifetime, if they had not acquired

HIV or contracted AIDS.

Why side-effects occur

South Korean researchers say they have identified

a key factor in the bodys rejection of transplanted

organs, raising hopes that the success rate of

transplant surgeries can be improved. A research

team, led by Dr Kim Sung-soo of Kyunghee

University, learned that cyclosporine, the anti-

rejection medication organ recipients must take

indefinitely, leads indirectly to organ rejection. It is

the first such finding, the team says. Researchers

found cyclosporine suppresses the work of a

protective protein called cyclophilin-A, or CyPA. This

in turn causes serious side effects, such asdeterioration of the kidneys, liver and nervous system,

in some cases even leading to death.

Korean doctors to study longer

The presidential special commission to improve the

national medical system and the development of the

health industry has decided to change degree

programs at medical colleges to six years, up from

the current four. The changes will take place

gradually between 2005 and 2007.


7/12



Korea

Stock Price (Won) Price change since Mkt Cap

Company Code Exchange Oct 25th Issue 24 1/1/02 1/1/01 (US$mil)

Share price movements ranked by performance since Jan 1st

Cho-A Pharm 34940 Kosdaq 18,500 6.6% 101.1% 50.4% 37Hanmi Pharm 08930 KSE 20,600 14.4% 60.3% 180.7% 113Ahn Gook Pharm 01540 Kosdaq 2,740 -0.4% 60.2% 166.0% 2Sam Sung Pharm 01360 KSE 5,050 -1.8% 49.0% 129.5% 21Sang-A Pharm 06280 KSE 6,500 -5.1% 34.6% 76.2% 26Daewon Pharm 03220 KSE 38,550 -3.7% 24.0% 127.8% 36Hanil Pharm 03040 KSE 3,050 3.0% 17.3% 131.1% 12Daewoong Pharm 03090 KSE 17,500 0.0% 14.4% 117.9% 157Handok Pharm 02390 KSE 38,500 2.1% 11.3% 78.2% 36Jin Yang Pharm 07370 Kosdaq 18,200 4.0% 4.0% 40.5% 10Sama Pharm 09300 Kosdaq 5,220 11.1% -1.9% 41.8% 28Whan In Pharm 16580 KSE 21,700 3.3% -2.0% -21.8% 34Hyundai Pharm 04310 KSE 11,250 6.1% -3.8% 23.4% 26

Dongsung Pharm 02210 KSE 4,915 2.4% -4.0% 19.6% 14Kyungdong Pharm 11040 Kosdaq 7,850 3.7% -4.3% 22.7% 39Shin Poong Pharm 19170 KSE 12,650 -10.9% -7.0% 115.9% 39Kukje Pharm 02720 KSE 6,400 1.6% -9.3% -4.9% 13Bukwang Pharm 03000 KSE 4,690 5.9% -11.0% 3.1% 86Sam Chun Dang Phar 00250 Kosdaq 1,480 4.2% -11.1% N/A 26Kwangdong Pharm 09290 KSE 1,000 4.7% -11.1% 29.9% 43Choong Wae Pharm 01060 KSE 7,710 5.6% -11.4% 31.5% 38Yuhan 00100 KSE 54,100 3.0% -13.4% 56.1% 293Pacific Pharmaceutic 16570 KSE 11350 3.7% -16.5% N/A 19Boryung Pharm 03850 KSE 12,350 2.5% -16.6% 7.9% 27Il Sung Pharm 03120 KSE 14,800 10.0% -17.3% 80.5% 32Yuyu 00220 KSE 18,000 -1.6% -17.4% -54.4% 17

Je Il Pharm 02620 KSE 22,600 -1.3% -18.3% 85.2% 27Samyang Optics 08080 KSE 1,165 1.3% -18.8% -75.7% 10Il Dong Pharm 00230 KSE 8,500 6.3% -20.9% 68.7% 24Dong-A Pharm 00640 KSE 18,350 3.7% -21.7% 60.0% 137Young Jin Pharm 03520 KSE 1,915 11.3% -23.4% -80.7% 20Korea Green Cross 05250 KSE 24100 -2.2% -23.6% N/A 95Dong Shin Pharm 06600 KSE 9000 15.4% -25.0% 63.6% 34Dongwha Pharm 00020 KSE 6,800 1.9% -26.0% 10.1% 31Il-Yang Pharm 07570 KSE 3,800 1.3% -26.2% -15.3% 22Orient 02630 KSE 5,120 2.4% -27.4% -24.5% 7Shin Dong Bang 04660 KSE 860 -2.3% -28.9% -47.6% 42Sinil Pharm 12790 Kosdaq 1,300 4.0% -31.9% 3.2% 9Su-Heung Capsule 08490 KSE 7870 10.8% -32.2% N/A 38

Mirae 25560 KSE 1,550 9.9% -32.3% 18.3% 157Hanall Pharm 09420 KSE 6950 2.7% -32.5% 45.1% 17Chong Kun Dang 01630 KSE 2,085 1.0% -33.6% -49.3% 20Sudo Pharm 04720 KSE 5,060 3.3% -38.3% -55.2% 12Samjin Pharm 05500 KSE 46,000 12.3% -40.3% -0.9% 82Macrogen 38290 Kosdaq 7940 4.1% -43.7% N/A 29Samil Pharm 00520 KSE 30500 13.0% -44.6% N/A 27Keun Wha Pharm 02250 KSE 13,200 26.9% -49.4% -34.0% 23Kuhm Pung Pharm 03060 KSE 415 -15.3% -55.9% -87.4% 9Daehan New Pharm 54670 Kosdaq 3,200 21.7% -57.9% N/A 16Hwail Pharm 61250 Kosdaq 8,900 -39.2% -70.1% N/A 26


8/12



India

Dr Reddys to appeal one decision,

applauds two others

Dr Reddys Laboratories says it will appeal a US

court decision that it infringed AstraZenecas patentson Prilosec. The court ruled that a generic made by

KUDCo, a unit of Germanys Schwarz Pharma, did

not infringe the patents but that the Dr Reddys

version and those of two other manufacturers did

(see Issue 24, p 8).

Meanwhile, the US FDA has given an approvable

letter for a new drug application (NDA) submitted

by Dr Reddys for amlodipine maleate, a generic

version of Pfizers US$2.5 billion a year drug

Norvasc. That means Dr Reddys is close tolaunching the drug for hypertension and angina. Final

approval is contingent upon the completion of ongoing

discussions the company has with the FDA regarding

specific chemistry manufacturing controls and

product labelling. The approval is also contingent upon

the outcome of patent-term extension litigation with

Pfizer, the patent holder for the drug.

Dr Reddys has additionally been included by Forbes

Global in a list of the 200 Best Small Companies in

the World. India had more companies than any otherAsian nation on the list, with 12 firms mentioned.

Ranbaxy enters South African HIV market

Ranbaxy has set up a 50:50 joint venture with Adcock

Ingram to sell Ranbaxys range of anti-retroviral

products in South Africa. The country is estimated

to have 5 million sufferers of HIV.

Shantha looks for US$25 million

Shantha Biotech is planning to raise US$25-30 million

by privately placing around 26% of its equity with a

strategic investor. The firm says 16 companies are

bidding for a slice and a deal is expected by earlyNovember. The proceeds will be used to set up a

manufacturing facility in Hyderabad next to the firms

exisitng operations. Plans for an overseas listing have

been delayed because of the global economic climate,

says the firm.

Lilly shines on SunEli Lilly has entered into an alliance with Sun

Pharmaceuticals under which Sun will start

manufacturing Lillys cardiovascular drugs for the

export and domestic Indian markets. The deal marks

another stage in the relationship of the two companies:

Sun already manufactures Lillys anti-diabetic

products. Lilly also works with Chennai-based Austin

Shasun for the manufacture of anesthesia, anti-TB

and peptic ulcer drugs. In a separate move, Lilly has

launched its sepsis drug, Xigris (drotrecogin alfa), in

India. The drug will be sold for Rs 500,000

(US$10,337) a dose. It is already sold in the US and

Australia, and is awaiting approval in Europe.

ATAGLANCESepsis

Around 1,400 people die every day in the world from

sepsis. The illness accounts for 70% of all deaths in

intensive care in the US.

Source: Eli Lilly

CORPORATERESULTSCompany Period/end Revenue Increase Net income Increase

Ranbaxy Laboratories 3Q/Sep 02 166.3 +49% 33.0 +79%

9M/Sep 02 428.3 +40% 81.2 +107%

Dr Reddys Laboratories 2Q/Sep 02 91.8 -14% 20.5 -31%

6M/Sep 02 169.2 +1% 37.1 -9%

Morepen Laboratories 2Q/Sep 02 30.6 +24% 3.5 +26%

6M/Sep 02 57.8 +18% 5.5 +26%

(Note: all figures in US$millions)


9/12


10/12


Published by Proof 100 Ltd. For a free subscription,

email [email protected] or visit www.proof100.com

WHEN WHAT WHERE DETAILS

Calendar

10

October 31st 10th International Healthcare Kuala Lumpur, c/o Reed Exhibitions Sdn Bhd,

Show 2002 Malaysia, Suite 312, Block F,

Phileo Damansara 1, Jalan 16/11

46350 Petaling Jaya, SelangorTel: 603-7660 3766

Fax:603-7958 1800


www.hospitals-malaysia.org

Nov 1st-2nd Korean Society of Anesthesiologists Seoul, Korea Deok Kim, MD

Tel: 011-82-2-760-2460

Fax: 011-82-2-744-1155

Nov 8th-10th 10th MASEAN Mid-term Meeting Singapore Secretary-General

Singapore Medical Association,

No. 2 College Road,Alumni Medical Centre, Level 2

Tel: 65-6223 1264

Fax: 65-6224 7827


Website: www.masean.org

Nov 9th-12th MediPhar Taipei - 14th Taipei Taipei, Taiwan Ms Irena Chang, Project Manager

International Medical Equipment Exhibition Section 3,

and Pharmaceuticals Show Exhibition Department,

CETRA,

Room 2A08, 5 Hsin-yi Road,

Sec. 5, Taipei 110Tel: 886-2-27251111 ext. 636

Fax: 886-2-27253501


www.taipeitradeshows.com.tw/mediphar/

Nov 10th-13th 12th International Symposium on Tokyo, Japan Bilingual Group Ltd,

Brain Edema and Brain Tissue Injury 2nd Fl., 4-7-22, Kudan-Minami,

Chiyoda-ku, Tokyo 102-0074

Tel: 03-3263 1261

Fax: 03-3263 1264


URL:square.umin.ac.jp/edema/

Nov 11th-12th 4th Asia Pacific Pharmaceuticals Beijing, China Helen Yu,

Round Table Conference Operations Manager,

Economist Conferences, Hong Kong

Tel: +852 2585 3316

asiapacific_customerservice@

economist.com

Nov 14th-17th 7th Asian Congress of Sexology Singapore Tel: +65 772 4261

Fax: +65 779 4753



11/12


11Published by Proof 100 Ltd. For a free subscription,email [email protected] or visit www.proof100.com

WHEN WHAT WHERE DETAILS

Calendar

Nov 21st-26th Digestive Diseases Week India Kerala, India Dr Philip Augustine,

Lakeshore Hospital & Research Ctr

NH 47 Bye Pass, Maradu,

Nettoor PO,Cochin 682-304, KeralaTel: 91-484 701032/701033

Fax: 91-484 701996


Nov 26th-30th 4th Asian Congress of SAR Hong Kong Miss Anthea Luk

Neurological Surgeons Tel: +852 21117574

Fax:+852 21110132


Website: www.Asiancns.org

Dec 1st-6th 10th APLAR Congress of Bangkok, Thailand Thai Rheumatism Association,

Rheumatology 9th Floor, Royal Golden Jubilee Bldg2 Soi Soonvijai, New Petchburi rd,

Bangkok, 10310, Thailand

Tel: 66-2-716 6524

Fax:66-2-716 6525



Website:www.aplar2002.com

December 2nd World Congress on Singapore Dr. T. Slavyanskaya

Immunopathology 16/10 Miklukho-Maklaya Street

117997 Moscow, Russia

Tel: 7-095-336 5000 / 7-095-429 9620

Fax: 7-095-336 5000


Website: www.isir.ru

Dec 4th-7th International Congress on Singapore Integrated Meetings Specialist Pte

Biomedical and Medical Lee Kai House Building,

Engineering 114 Middle Road,

#05-01 Singapore 188971

Tel: 65-226 3069

Fax: 65-226 3016


2003

Feb 19th-22nd 12th World Congress on Cardiac SAR Hongkong Dr Tse Tak-fu

Pacing and Electrophysiology Tel: +852 2527 8285

Fax: +852 2865 0943

Aug 13th-16th NephroAsia 2003 Singapore Philip Paul

International Marketing Manager,

World Kidney Fund

National Kidney Foundn Singapore

81 Kim Keat Road



12/12



CompaniesCompanies mentionedAdcock Ingram ............................................................. 8

AstraZeneca .............................................................. 2,8

Austin Shasun .............................................................. 8

Banyu Pharmaceutical ................................................... 2

Biotech Medical ............................................................ 5Bristol-Myers Squibb .................................................... 5

Chugai Pharmaceutical .................................................. 2

Dr Reddys Laboratories ............................................ 6,8

DuoPharma Biotech ...................................................... 6

Eli Lilly .......................................................................... 8

GeneSoft ....................................................................... 6

GlaxoSmithKline ....................................................... 2,4,5

GPO ............................................................................... 5

Green Cross ................................................................... 2

Innovative Biotech ....................................................... 5

Kawasumi Laboratories .............................................. 2,6

Kissei Pharmaceutical ................................................... 2KUDCo ......................................................................... 8

LaserSight ..................................................................... 4

LG Life Sciences............................................................ 6

MerLion Pharmaceuticals.............................................. 5

Mitsubishi Pharma ........................................................ 2

Morepen Laboratories .................................................. 8

Nabi ............................................................................... 5

Nihon Seiyaku............................................................... 2

Novartis ..................................................................... 2,6

Pharmaniaga.................................................................. 5

Pfizer .......................................................................... 5,8

Ranbaxy Laboratories ................................................... 8

Roche Holdings ............................................................ 2

Shantha Biotech ............................................................ 8

Schwarz Pharma ............................................................ 8

Shenzhen New Industries Medical Development ......... 4

Sun Pharmaceuticals ..................................................... 8

Tanabe Seiyaku ............................................................. 2

Tong Jum Chew............................................................. 5

Yunnan Baiyao .............................................................. 5

Research centersAaron Diamond AIDS Research Center (US) ................ 4Centre for Natural Product Research (Singapore) ......... 5

Chinese Academy of Medical Sciences ........................ 4

Inst of Molecular and Cell Biology (Singapore)............ 5

Korea Inst for Health and Social Affairs ....................... 6

Kyunghee University (Korea) ....................................... 6

National Science Council (Taiwan) ............................... 4

National University of Singapore.................................. 5

Nippon Medical School (Japan) .................................... 2

Third Military Medical University (China) .................... 4

Exchange rates used in this issue

Currency ................................................. Rate per US$

British Pound Sterling () ........................................ 0.64Chinese Yuan .......................................................... 8.28

Euro......................................................................... 1.02

Hong Kong Dollar (HK$) ........................................ 7.80

Indian Rupee (Rs) ................................................. 48.37

Indonesian Rupiah ................................................ 9,200

Japanese Yen () ..................................................124.32

Korean Won .......................................................... 1,232

Malaysian Ringgit (RM) ......................................... 3.80

Singapore Dollar (S$) .............................................. 1.77

Taiwanese Dollar (NT$) ......................................... 34.80

Thai Baht .............................................................. 43.42

ASIANMEDICALINDUSTRYNEWS

SUBSCRIPTIONSTOOUR

NEWSLETTERARECOMPLETELY

FREE

EMAILUSON

[email protected]

ORVISIT

WWW.PROOF100.COM

FORYOURCOPY

PROOF

100PUBLISHING

Documents

Asian Med News_October 2002